Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn's disease.

Ther Adv Gastroenterol · 2023 · PMC9989393 · PMID 36895282

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

A post-hoc analysis of data from the GEMINI 2 trial showed a trend toward better fistula healing on VDZ maintenance than placebo (28% with fistula closure versus 11% at week 14), though it was not statistically significant. 23 A separate post-hoc analysis of the ENTERPRISE study comparing two VDZ regimens reported 43% of patients had perianal fistula closure at we

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.